Current and future trends in biomarker discovery and development of companion diagnostics for arthritis

Expert Review of Molecular Diagnostics

Volumn 15, Issue 2, 2015, Pages 219-234

  Gibson, David S ^a   Bustard, Michael J ^a   Mcgeough, Cathy M ^a   Murray, Helena A ^b   Crockard, Martin A ^b   Mcdowell, Andrew ^a   Blayney, Jayne K ^a   Gardiner, Philip V ^c   Bjourson, Anthony J ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b Randox Laboratories Ltd   (United Kingdom)

^c ALTNAGELVIN HOSPITAL   (United Kingdom)

Author keywords

bioinformatics; companion diagnostics; genomics; imaging; microbiomics; proteomics; rheumatology, stratified medicine

Indexed keywords

BIOLOGICAL MARKER; METHOTREXATE; PROTEIN; ANTIRHEUMATIC AGENT;

BIOINFORMATICS; BIOLOGICAL THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE ACTIVITY; EPIGENETICS; GENETIC VARIABILITY; HUMAN; INTESTINE FLORA; LABORATORY TEST; META ANALYSIS (TOPIC); MICROBIOME; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PHARMACOGENOMICS; PROGNOSTIC ASSESSMENT; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SCORING SYSTEM; ANIMAL; ARTHRITIS, RHEUMATOID; BIOLOGY; GASTROINTESTINAL TRACT; GENETICS; METABOLISM; MICROBIOLOGY; MICROFLORA; MOLECULAR DIAGNOSIS; PERSONALIZED MEDICINE; TRENDS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COMPUTATIONAL BIOLOGY; GASTROINTESTINAL TRACT; HUMANS; INDIVIDUALIZED MEDICINE; MICROBIOTA; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 84921403632     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.969244     Document Type: Review

References (141)

1. Angulo B, Lopez-Rios F, Gonzalez D. A new generation of companion diagnostics: cobas BRAF, KRAS and EGFR mutation detection tests. Expert Rev Mol Diagn 2014;14(5):517-24
2. Fridlyand J, Simon RM, Walrath JC, et al. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat Rev Drug Discov 2013;12(10):743-55
3. Zhang CH, Zhang YP. Maximizing the commercial value of personalized therapeutics and companion diagnostics. Nat Biotechnol 2013;31(9):803-5
4. Smith SL, Plant D, Eyre S, Barton A. The potential use of expression profiling: implications for predicting treatment response in rheumatoid arthritis. Ann Rheum Dis 2013;72(7):1118-24
5. Gibson DS, Rooney ME, Finnegan S, et al. Biomarkers in rheumatology, now and in the future. Rheumatology (Oxford) 2012; 51(3):423-33
6. Bell J. Stratified medicines: towards better treatment for disease. Lancet 2014; 383(Suppl 1):S3-5
7. Hocking LJ, Rivadeneira F. Stratified medicine approaches for the treatment of musculoskeletal disorders. Curr Opin Pharmacol 2014;16C:127-32
8. Vanarsa K, Mohan C. Proteomics in rheumatology: the dawn of a new era. F1000 Med Rep 2010;2:87-7
9. Fitzgerald SP, Lamont JV, McConnell RI, Benchikh el O. Development of a high-Throughput automated analyzer using biochip array technology. Clin Chem 2005; 51(7):1165-76
10. Ceroni A, Sibani S, Baiker A, et al. Systematic analysis of the IgG antibody immune response against varicella zoster virus (VZV) using a self-Assembled protein microarray. Mol Biosyst 2010;6(9):1604-10
11. Wong J, Sibani S, Lokko NN, et al. Rapid detection of antibodies in sera using multiplexed self-Assembling bead arrays. J Immunol Methods 2009;350(1-2):171-82
12. Boja E, Hiltke T, Rivers R, et al. Evolution of clinical proteomics and its role in medicine. J Proteome Res 2011;10(1):66-84
13. Robinson WH, Lindstrom TM, Cheung RK, Sokolove J. Mechanistic biomarkers for clinical decision making in rheumatic diseases. Nat Rev Rheumatol 2013;9(5):267-76
14. Dawes PT, Fowler PD, Clarke S, et al. Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. Br J Rheumatol 1986;25(1):44-9
15. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res The 2005;7(4): R796-806
16. van Leeuwen MA, van Rijswijk MH, Sluiter WJ, et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997;24(1):20-7
17. Young-Min S, Cawston T, Marshall N, et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007;56(10): 3236-47
18. Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54(3):702-10
19. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46(6):1451-9
20. Sharif M, Shepstone L, Elson CJ, et al. Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee. Ann Rheum Dis 2000;59(1):71-4
21. Smith JW, Martins TB, Gopez E, et al. Significance of C-reactive protein in osteoarthritis and total knee arthroplasty outcomes. Ther Adv Musculoskelet Dis 2012;4(5):315-25
22. Schmid FR, Roitt IM, Rocha MJ. Complement fixation by a two-component antibody system, immunoglobulin G and immunoglobulin M anti-globulin (rheumatoid factor): paradoxical effect related to immunoglobulin G concentration. J exp Med 1970;132-673
23. van Zeben D, Hazes JM, Zwinderman AH, et al. Factors predicting outcome of rheumatoid arthritis: results of a followup study. J Rheumatol 1993;20(8):1288-96
24. Smolen JS, Tohidast-Akrad M, Gal A, et al. The role of T-lymphocytes and cytokines in rheumatoid arthritis. Scand J Rheumatol 1996;25(1):1-4
25. Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101(1):273-81
26. Vallbracht I, Rieber J, Oppermann M, et al. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004; 63(9):1079-84
27. Sokolove J, Zhao X, Chandra PE, Robinson WH. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor. Arthritis Rheum 2011;63(1):53-62
28. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50(3):709-15
29. Mierau R, Genth E. Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis. Clin Chem Lab Med 2006;44(2):138-43
30. Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/.European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62(9):2569-81
31. van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007;56(5):1424-32
32. Martinez A, Salido M, Bonilla G, et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 2004;50(4):1077-82
33. Lindstrom TM, Robinson WH. Biomarkers for rheumatoid arthritis: making it personal. Scand J Clin Lab Invest Suppl 2010;242: 79-84
34. Meeuwisse CM, van der Linden MP, Rullmann TA, et al. Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. Arthritis Rheum 2011; 63(5):1265-73
35. Rosengren S, Wei N, Kalunian KC, et al. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford) 2011; 50(3):603-10
36. Hueber W, Tomooka BH, Batliwalla F, et al. Blood autoantibody and cytokine profiles predict response to anti-Tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther 2009;11(3):R76
37. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol 2007;28(11):482-90
38. van den Broek M, Klarenbeek NB, Dirven L, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011; 70(8):1389-94
39. Jonas DE, Wines R. Pharmacogenomic testing and the prospect of individualized treatment. N C Med J 2013;74(6):485-93
40. Szekanecz Z, Mesko B, Poliska S, et al. Pharmacogenetics and pharmacogenomics in rheumatology. Immunol Res 2013;56(2-3): 325-33
41. Plant D, Bowes J, Potter C, et al. Genome-wide association study of genetic predictors of anti-Tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 2011;63(3): 645-53
42. Plant D, Wilson AG, Barton A. Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol 2014;10(6):329-37
43. Karsdal MA, Christiansen C, Ladel C, et al. Osteoarthritis-A case for personalized health care?. Osteoarthritis Cartilage 2014;22(1): 7-16
44. Barrera P, van der Maas A, van Ede AE, et al. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-Tumour necrosis factor-Alpha antibody compared with methotrexate in long-standing rheumatoid arthritis. Rheumatology (Oxford) 2002;41(4):430-9
45. Davila L, Ranganathan P. Pharmacogenetics: implications for therapy in rheumatic diseases. Nat Rev Rheumatol 2011;7(9):537-50
46. Lee YH, Song GG. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-Analysis. Clin Drug Investig 2010; 30(2):101-8
47. Owen SA, Lunt M, Bowes J, et al. MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-Analysis of C677T and A1298C polymorphisms. Pharmacogenomics J 2013;13(2):137-47
48. Wessels JA, van der Kooij SM, le Cessie S, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007;56(6): 1765-75
49. Kooloos WM, Wessels JA, van der Straaten T, et al. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics 2010;11(2): 163-75
50. Fransen J, Kooloos WM, Wessels JA, et al. Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. Pharmacogenomics 2012; 13(9):1087-94
51. O'Rielly DD, Roslin NM, Beyene J, et al. TNF-Alpha-308 G/A polymorphism and responsiveness to TNF-Alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-Analysis. Pharmacogenomics J 2009; 9(3):161-7
52. Pavy S, Toonen EJ, Miceli-Richard C, et al. Tumour necrosis factor alpha-308G-A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-Analysis. Ann Rheum Dis 2010;69(6):1022-8
53. Zeng Z, Duan Z, Zhang T, et al. Association between tumor necrosis factor-Alpha (TNF-Alpha) promoter-308 G/.A and response to TNF-Alpha blockers in rheumatoid arthritis: a meta-Analysis. Mod Rheumatol 2013;23(3):489-95
54. McGeough CM, Berrar D, Wright G, et al. Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-Alpha therapy. Rheumatol Int 2012;32(6):1647-53
55. Soliman MM, Hyrich KL, Lunt M, et al. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol 2012;39(2): 240-6
56. Meier FM, Frerix M, Hermann W, Muller-Ladner U. Current immunotherapy in rheumatoid arthritis. Immunotherapy 2013;5(9):955-74
57. Viatte S, Plant D, Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 2013;9(3):141-53
58. Karouzakis E, Gay RE, Michel BA, et al. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009;60(12):3613-22
59. Liu CC, Fang TJ, Ou TT, et al. Global DNA methylation, DNMT1, and MBD2 in patients with rheumatoid arthritis. Immunol Lett 2011;135(1-2):96-9
60. Liu Y, Aryee MJ, Padyukov L, et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol 2013;31(2):142-7
61. Laird PW. Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet 2010;11(3):191-203
62. Ellis JA, Munro JE, Chavez RA, et al. Genome-scale case-control analysis of CD4+ T-cell DNA methylation in juvenile idiopathic arthritis reveals potential targets involved in disease. Clin Epigenetics 2012; 4(1):20
63. Gerlag DM, Tak PP. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials. Best Pract Res Clin Rheumatol 2008;22(2):311-23
64. Tas SW. Personalised treatment of arthritis in the next eRA. Neth J Med 2009;67(11): 362-3
65. Ringold S, Lu L, Wallace CA, et al. A7: initial Assessment of Multi-biomarker Disease Activity Assay in JIA. Arthritis Rheumatol 2014;66(Suppl 11):S10-11
66. Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature 2007;449(7164):804-10
67. Baquero F, Nombela C. The microbiome as a human organ. Clin Microbiol Infect 2012;18(Suppl 4):2-4
68. Prakash S, Rodes L, Coussa-Charley M, Tomaro-Duchesneau C. Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics 2011;5:71-86
69. Saad R, Rizkallah MR, Aziz RK. Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-Associated microbes. Gut Pathog 2012;4(1):16
70. Kinross JM, Darzi AW, Nicholson JK. Gut microbiome-host interactions in health and disease. Genome Med 2011;3(3):14
71. Rogler G, Rosano G. The heart and the gut. Eur Heart J 2014;35(7):426-30
72. Dinan TG, Cryan JF. Melancholic microbes: a link between gut microbiota and depression?. Neurogastroenterol Motil 2013;25(9):713-19
73. Scher JU, Abramson SB. The microbiome and rheumatoid arthritis. Nat Rev Rheumatol 2011;7(10):569-78
74. Wu HJ, Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010;32(6):815-27
75. Scher JU, Ubeda C, Equinda M, et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum 2012;64(10):3083-94
76. Gomez A, Luckey D, Yeoman CJ, et al. Loss of sex and age driven differences in the gut microbiome characterize arthritis-susceptible 0401 mice but not arthritis-resistant 0402 mice. PLoS One 2012;7(4):e36095
77. Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2013;2:e01202
78. Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2011;108(Suppl 1):4615-22
79. Luckey D, Gomez A, Murray J, et al. Bugs &us: the role of the gut in autoimmunity. Indian J Med Res 2013; 138(5):732-43
80. Nibali L, Henderson B, Sadiq ST, Donos N. Genetic dysbiosis: the role of microbial insults in chronic inflammatory diseases. J Oral Microbiol 2014;6
81. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368(5):407-15
82. Borody TJ, Paramsothy S, Agrawal G. Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep 2013;15(8):337
83. Vaghef-Mehrabany E, Alipour B, Homayouni-Rad A, et al. Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. Nutrition 2014;30(4):430-5
84. So JS, Kwon HK, Lee CG, et al. Lactobacillus casei suppresses experimental arthritis by down-regulating T helper 1 effector functions. Mol Immunol 2008; 45(9):2690-9
85. van der Heijde DM, van 'Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49(11): 916-20
86. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364(9430):263-9
87. Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007; 66(Suppl 3):iii56-60
88. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/.European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70(3):404-13
89. Brown AK, Conaghan PG, Karim Z, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008;58(10): 2958-67
90. Andersen M, Ellegaard K, Hebsgaard JB, et al. Ultrasound colour Doppler is associated with synovial pathology in biopsies from hand joints in rheumatoid arthritis patients: a cross-sectional study. Ann Rheum Dis 2014;73(4):678-83
91. Hameed B, Pilcher J, Heron C, Kiely PD. The relation between composite ultrasound measures and the DAS28 score, its components and acute phase markers in adult RA. Rheumatology (Oxford) 2008; 47(4):476-80
92. Kawashiri SY, Kawakami A, Iwamoto N, et al. The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomarkers in patients with rheumatoid arthritis. Rheumatology (Oxford) 2011; 50(5):962-5
93. Naredo E, Bonilla G, Gamero F, et al. Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. Ann Rheum Dis 2005;64(3):375-81
94. Damjanov N, Radunovic G, Prodanovic S, et al. Construct validity and reliability of ultrasound disease activity score in assessing joint inflammation in RA: comparison with DAS-28. Rheumatology (Oxford) 2012; 51(1):120-8
95. Hetland ML, Ejbjerg B, Horslev-Petersen K, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009; 68(3):384-90
96. Backhaus M, Ohrndorf S, Kellner H, et al. Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthritis Rheum 2009;61(9): 1194-201
97. Poste G. Bring on the biomarkers. Nature 2011;469(7329):156-7
98. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487(7407):330-7
99. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474(7353):609-15
100. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010; 233(1):233-55
101. Lequerre T, Bansard C, Vittecoq O, et al. Early and long-standing rheumatoid arthritis: distinct molecular signatures identified by gene-expression profiling in synovia. Arthritis Res Ther 2009;11(3):R99
102. Julia A, Erra A, Palacio C, et al. An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. PLoS One 2009;4(10):e7556
103. Bakker MF, Jacobs JW, Welsing PM, et al. Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis 2011;70(6):1099-103
104. Centola M, Cavet G, Shen Y, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One 2013;8(4):e60635
105. Bakker MF, Cavet G, Jacobs JW, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis 2012;71(10):1692-7
106. Wessels JA, van der Kooij SM, le Cessie S, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007;56(6): 1765-75
107. Koczan D, Drynda S, Hecker M, et al. Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 2008;10(3):R50
108. Toonen EJ, Gilissen C, Franke B, et al. Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis. PLoS One 2012;7(3):e33199
109. Marquez A, Ferreiro-Iglesias A, Davila-Fajardo CL, et al. Lack of validation of genetic variants associated with anti-Tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-Analysis. Arthritis Res Ther 2014; 16(2):R66
110. Lohmueller KE, Pearce CL, Pike M, et al. Meta-Analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003;33(2):177-82
111. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43(1):22-9
112. Kanters S, Druyts E, Mills EJ, Thorlund K. What drives the comparative effectiveness of biologics vs methotrexate in rheumatoid arthritis?. Meta-regression and graphical inspection of suspected clinical factors. Rheumatology (Oxford) 2014;53(7): 1264-73
113. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376(9746):1094-108
114. Miao CG, Yang YY, He X, Li J. New advances of DNA methylation and histone modifications in rheumatoid arthritis, with special emphasis on MeCP2. Cell Signal 2013;25(4):875-82
115. de la Rica L, Urquiza JM, Gomez-Cabrero D, et al. Identification of novel markers in rheumatoid arthritis through integrated analysis of DNA methylation and microRNA expression. J Autoimmun 2013;41:6-16
116. Krabben A, Huizinga TW, van der Helm-van Mil AH. Undifferentiated arthritis characteristics and outcomes when applying the 2010 and 1987 criteria for rheumatoid arthritis. Ann Rheum Dis 2012;71(2):238-41
117. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376(9746):1094-108
118. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014; 73(1):62-8
119. Bansard C, Lequerre T, Daveau M, et al. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?. Rheumatology (Oxford) 2009;48(9):1021-8
120. Marsal S, Julia A. Rheumatoid arthritis pharmacogenomics. Pharmacogenomics 2010;11(5):617-19
121. Miossec P, Verweij CL, Klareskog L, et al. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis 2011; 70(10):1713-18
122. Lima A, Bernardes M, Sousa H, et al. SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients. Pharmacogenomics 2014;15(6):807-20
123. Lee YH, Song GG. Association between C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-Analysis. Clin Drug Investig 2010; 30(2):101-108
124. Weisman MH, Furst DE, Park GS, et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 2006; 54(2):607-12
125. Takatori R, Takahashi KA, Tokunaga D, et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol 2006;24(5):546-54
126. Kumagai K, Hiyama K, Oyama T, et al. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003; 11(5):593-600
127. Tolusso B, Pietrapertosa D, Morelli A, et al. IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics 2006;7(5): 683-95
128. Aslibekyan S, Brown EE, Reynolds RJ, et al. Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis: results from the treatment of early aggressive rheumatoid arthritis trial. Pharmacogenomics J 2014; 14(1):48-53
129. Maxwell JR, Potter C, Hyrich KL, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008;17(22):3532-8
130. Kang CP, Lee KW, Yoo DH, et al. The influence of a polymorphism at position-857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford) 2005;44(4):547-52
131. Plant D, Prajapati R, Hyrich KL, et al. Replication of association of the PTPRC gene with response to anti-Tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum 2012;64(3):665-70
132. Cui J, Saevarsdottir S, Thomson B, et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-Tumor necrosis factor alpha therapy. Arthritis Rheum 2010;62(7):1849-61
133. Tan RJ, Gibbons LJ, Potter C, et al. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-Tumour necrosis factor treatment. Ann Rheum Dis 2010;69(6):1029-35
134. Bowes JD, Potter C, Gibbons LJ, et al. Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet Genomics 2009;19(4): 319-23
135. Coulthard LR, Taylor JC, Eyre S, et al. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis 2011;70(1):98-103
136. Potter C, Cordell HJ, Barton A, et al. Association between anti-Tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis 2010; 69(7):1315-20
137. Acosta-Colman I, Palau N, Tornero J, et al. GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics 2013;14(7): 727-34
138. Sode J, Vogel U, Bank S, et al. Anti-TNF treatment response in rheumatoid arthritis patients is associated with genetic variation in the NLRP3-inflammasome. PLoS One 2014;9(6):e100361
139. Quartuccio L, Fabris M, Pontarini E, et al. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann Rheum Dis 2014; 73(4):716-21
140. Ruyssen-Witrand A, Rouanet S, Combe B, et al. Association between-871CT promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients. Rheumatology (Oxford) 2013;52(4):636-41
141. Wang J, Bansal AT, Martin M, et al. Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J 2013;13(3):235-41